PL3986419T3 - BORONIC ACID DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS - Google Patents

BORONIC ACID DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS

Info

Publication number
PL3986419T3
PL3986419T3 PL20827883.8T PL20827883T PL3986419T3 PL 3986419 T3 PL3986419 T3 PL 3986419T3 PL 20827883 T PL20827883 T PL 20827883T PL 3986419 T3 PL3986419 T3 PL 3986419T3
Authority
PL
Poland
Prior art keywords
acid derivatives
boronic acid
therapeutic applications
therapeutic
applications
Prior art date
Application number
PL20827883.8T
Other languages
Polish (pl)
Inventor
Olga Lomovskaya
Original Assignee
Qpex Biopharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qpex Biopharma, Inc. filed Critical Qpex Biopharma, Inc.
Publication of PL3986419T3 publication Critical patent/PL3986419T3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL20827883.8T 2019-06-19 2020-06-17 BORONIC ACID DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS PL3986419T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962863752P 2019-06-19 2019-06-19
PCT/US2020/038171 WO2020257306A1 (en) 2019-06-19 2020-06-17 Boronic acid derivatives and therapeutic uses thereof

Publications (1)

Publication Number Publication Date
PL3986419T3 true PL3986419T3 (en) 2025-09-08

Family

ID=74040882

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20827883.8T PL3986419T3 (en) 2019-06-19 2020-06-17 BORONIC ACID DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS

Country Status (13)

Country Link
US (1) US20230144152A1 (en)
EP (2) EP3986419B1 (en)
CN (1) CN114340639A (en)
DK (1) DK3986419T3 (en)
ES (1) ES3036963T3 (en)
FI (1) FI3986419T3 (en)
HR (1) HRP20250815T1 (en)
HU (1) HUE072159T2 (en)
LT (1) LT3986419T (en)
PL (1) PL3986419T3 (en)
PT (1) PT3986419T (en)
SI (1) SI3986419T1 (en)
WO (1) WO2020257306A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX389349B (en) 2016-06-30 2025-03-20 Qpex Biopharma Inc BORONIC ACID DERIVATIVES AND THEIR THERAPEUTIC USES.
EP3781576B1 (en) 2018-04-20 2024-06-12 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
AU2021266715A1 (en) 2020-05-05 2022-11-17 Qpex Biopharma, Inc. Boronic acid derivatives and synthesis, polymorphic forms, and therapeutic uses thereof
JP2024512793A (en) * 2021-04-05 2024-03-19 キューペックス バイオファーマ, インコーポレイテッド Ceftibuten dosing regimen
JP2026504522A (en) * 2023-02-08 2026-02-05 キューペックス バイオファーマ, インコーポレイテッド Methods for determining siderophore beta-lactam susceptibility

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
US7271186B1 (en) 2002-12-09 2007-09-18 Northwestern University Nanomolar β-lactamase inhibitors
CA2705393A1 (en) 2007-11-13 2009-05-22 Protez Pharmaceuticals, Inc. Beta-lactamase inhibitors
EP3139930B1 (en) * 2014-05-05 2024-08-14 Melinta Therapeutics, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
AU2015264418A1 (en) 2014-05-19 2016-11-10 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2017100537A1 (en) * 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
MX389349B (en) * 2016-06-30 2025-03-20 Qpex Biopharma Inc BORONIC ACID DERIVATIVES AND THEIR THERAPEUTIC USES.
WO2018075084A1 (en) 2016-10-20 2018-04-26 Symbol Technologies, Llc Mobile device with edge activation
US11286270B2 (en) * 2017-10-11 2022-03-29 Qpex Biopharma, Inc. Boronic acid derivatives and synthesis thereof

Also Published As

Publication number Publication date
EP3986419A1 (en) 2022-04-27
EP3986419A4 (en) 2023-07-12
HUE072159T2 (en) 2025-10-28
EP4599892A3 (en) 2025-09-10
EP3986419B1 (en) 2025-05-14
ES3036963T3 (en) 2025-09-25
TW202114706A (en) 2021-04-16
SI3986419T1 (en) 2025-09-30
WO2020257306A1 (en) 2020-12-24
HRP20250815T1 (en) 2025-09-12
EP4599892A2 (en) 2025-08-13
LT3986419T (en) 2025-08-25
CN114340639A (en) 2022-04-12
FI3986419T3 (en) 2025-07-24
DK3986419T3 (en) 2025-08-04
PT3986419T (en) 2025-07-31
US20230144152A1 (en) 2023-05-11

Similar Documents

Publication Publication Date Title
DK3478693T3 (en) BORONIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF
PL3917616T3 (en) HETEROCYCLIC COMPOUNDS AND THEIR APPLICATIONS
CY1124407T1 (en) AUTOTAXIN INHIBITOR COMPOUNDS
PL3986419T3 (en) BORONIC ACID DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS
EP3781576C0 (en) BORIC ACID DERIVATIVES AND THERAPEUTIC USES THEREOF
IL277640A (en) Human and cellular BCMA antibody - BCMA-CAR
DK3565550T3 (en) PHARMACEUTICAL COMPOSITIONS INCLUDING MELOXICAM AND RIZATRIPTANE
PL4234581T3 (en) THERAPEUTIC ANTIBODIES AND THEIR APPLICATIONS
HUE052468T2 (en) Arginase inhibitors and their therapeutic applications
IL291191A (en) cdk inhibitors and their use as drugs
PL3555076T3 (en) New derivatives of phenylpropionic acid and their applications
LT4331584T (en) THERAPEUTIC USES OF LANIFIBRANOR DEUTERINE DERIVATIVES
DK3786160T3 (en) PYRIDINE DERIVATIVES AND THERAPEUTIC USES THEREOF AS TRPC6 INHIBITORS
HUE036672T2 (en) Pyrazole amide compound and therapeutic applications
DK3514153T3 (en) PYRIMIDINE COMPOUND AND PHARMACEUTICAL USE
DK3255042T3 (en) HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME
PL3618848T3 (en) BIOLOGICALLY ACTIVE COMPLEXES AND THEIR THERAPEUTIC APPLICATIONS
EP3750553A4 (en) PSORIASIS THERAPEUTIC AGENT
DK3615514T3 (en) PROPIONIC ACID DERIVATIVES AND THEIR USES
EP3526186A4 (en) SUBSTITUTED HYDROXYSTILBENS AND THEIR THERAPEUTIC APPLICATIONS
IL263506A (en) Topical formulations of pde-4 inhibitors and methods of using them
DK2958573T3 (en) PHARMACEUTICAL FORMULATIONS OF NITRITES AND APPLICATIONS THEREOF
DK3919498T6 (en) PYRROLOPYRIMIDE DERIVATIVES AND USE THEREOF
EP3601223A4 (en) ISOTOPE-ENriched 3-AMINO-1-PROPANESULPHONIC ACID DERIVATIVES AND USES THEREOF
PL3452441T3 (en) Alpha-truxylic acid derivatives and pharmaceutical compositions thereof